Hepatology Unit and Laboratory of Molecular Genetics and Pathology of Hepatitis Viruses, Reference Center of the Tuscany Region for Chronic Liver Disease and Cancer, Department of Medical Specialties, University Hospital of Pisa, Via Paradisa 2, 56124 Pisa, Italy.
Institute of Biostructure and Bioimaging, National Research Council, Via De Amicis 95, 80145 Naples, Italy.
Viruses. 2022 Mar 28;14(4):701. doi: 10.3390/v14040701.
The currently available antiviral treatments (Peg-Interferon-α and Nucleos(t)ide Analogues, NA) for chronic hepatitis B (CHB) achieve a functional cure (serum HBsAg and HDV-DNA clearance) of HBV infection in a limited number of patients. Nevertheless, the continuous pharmacological suppression of viral replication by NA halts liver disease progression lowering the risk of HCC development and improving the survival. In the near future, to fully exploit the potential of old and new drugs for HBV treatment a personalized approach to the patients will be required according to an accurate definition of their virologic, immunologic and clinical profile.
目前用于慢性乙型肝炎（CHB）的抗病毒治疗（聚乙二醇干扰素-α 和核苷（酸）类似物，NA）在少数患者中实现了 HBV 感染的功能性治愈（血清 HBsAg 和 HDV-DNA 清除）。然而，NA 通过持续抑制病毒复制来阻止肝病进展，降低 HCC 发展的风险并提高生存率。在不久的将来，为了充分利用现有和新的抗乙肝病毒药物的潜力，需要根据患者的病毒学、免疫学和临床特征进行个体化治疗。
